Long-term survival and toxicity profile of patients with disseminated neuroendocrine tumors following multiple cycles of high activity 111In pentetreotide therapy.

e13545 Background: We have previously reported clinical response to multiple doses of high activity 111In pentetreotide in patients with disseminated neuroendocrine tumors. Here we report long term renal toxicity and survival following multiple 500 mCi doses of 111In-pentetreotide. Methods: In a nonrandomized trial, 83 patients (50 men, 33 women) with disseminated neuroendocrine tumor (stages III to IV) received 500mCi doses of In-111 pentetreotide therapy without co-administration of amino acid solution. Twenty-one patients received one therapy with an average dose of 489mCi/patient (390-513 mCi) and average renal dose of 330 rad (134-712 rad). Forty-one patients received two cycles of therapies with an average dose 977mCi/patient (893-1,012 mCi/patient) and cumulative renal dose of 566 rad (63-578 rad). Twenty-one patients received three therapies with an (average dose 1,464 mCi/patient (1,419-1,495mCi) and cumulative average renal dose of 665 rad (329-2,273 rad). Patients were evaluated for evidence of...